Report #2853167

Received Aug 7, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Male
Age: 65 yrs
State: —
Recovered: Unknown
Vaccinated: Jan 1, 2025
Onset: Jan 1, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
HEPA	HEP A (HAVRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	T9TL9	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

received the fist dose of Havrix in October of 2024 and the second dose in January of 2025.; This non-serious case was reported by a nurse via call center representative and described the occurrence of drug dose administration interval too short in a 65-year-old male patient who received HAV (Havrix) (batch number T9TL9, expiry date 05-DEC-2025) for prophylaxis. Previously administered products included Havrix (received 1st dose in October 2024). In JAN-2025, the patient received the 2nd dose of Havrix. In JAN-2025, an unknown time after receiving Havrix, the patient experienced drug dose administration interval too short (Verbatim: received the fist dose of Havrix in October of 2024 and the second dose in January of 2025.). The outcome of the drug dose administration interval too short was not applicable. Additional Information: GSK Receipt Date: 29-JUL-2025 The nurse reports a patient received the first dose of Havrix vaccine in October of 2024 and the second dose in January of 2025. The patient received 2nd dose of Havrix vaccine earlier than recommended interval, which led to shortening of vaccination schedule.